An observational study in patients who received nivolumab preoperatively for stage 1 non-small cell lung cancer considered as high-risk of relapse

JRCT ID: jRCT1060190007

Registered date:18/06/2019

Basic Information

• Recruitment status: Not Recruiting
• Health condition(s) or Problem(s) studied: non small cell lung cancer
• Date of first enrollment: 05/07/2019
• Target sample size: 50
• Study type: Observational

Outcome(s)

• Primary Outcome: overall survival
• Secondary Outcome: progression-free survival

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1.Patients enrolled and received nivolumab therapy in the POTENTIAL study.
2.Subjects who were fully informed beforehand about their participation in this observational study and agreed to participate in the study in writing.

• Exclude criteria: 1.Patients who are limited, or predicted to be limited, for participation of this study by geographic or social factors during the study period.

Related Information

• Primary Sponsor: Okada Morihito
• Source(s) of Monetary Support: ONO PHARMACEUTICAL CO., LTD.